IMRX - NASDAQ
Immuneering Corporation
$4.55
+3.4%Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
At a Glance
Live Snapshotimrx
Cash at Beginning of Period
Last Annual Value
36.14M
3-Year CAGR
-22%
5-Year CAGR
21%
10-Year CAGR
42%
Immuneering Corporation Competitors Analysis of Cash at Beginning of Period
| Company | Cash at Beginning of Period | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Immuneering Corporation NASDAQ:IMRX | 36.14M | -20.8% | -0.5% | N/A | |
 Foghorn Therapeutics Inc. NASDAQ:FHTX | 57.16M | 2.0% | -9.6% | N/A | |
 Humacyte, Inc. NASDAQ:HUMA | 95.29M | -14.0% | 19.0% | N/A | |
 Codexis, Inc. NASDAQ:CDXS | 20.83M | -43.6% | -32.7% | -1.1% | |
 Corbus Pharmaceuticals Holdings, Inc. NASDAQ:CRBP | 17.87M | 1.3% | -27.0% | 3.7% | |
 Neonc Technologies Holdings, Inc. NASDAQ:NTHI | 64.89K | -53.2% | -17.7% | N/A | |
 Cassava Sciences, Inc. NASDAQ:SAVA | 128.57M | -13.8% | 6.6% | 15.2% | |
 Sangamo Therapeutics, Inc. NASDAQ:SGMO | 43.42M | -24.8% | -20.0% | -4.6% | |
 SELLAS Life Sciences Group, Inc. NASDAQ:SLS | 13.99M | -6.7% | -17.0% | -7.3% | |
 Protara Therapeutics, Inc. NASDAQ:TARA | 163.54M | 87.3% | -0.7% | 15.1% | |
 Nautilus Biotechnology, Inc. NASDAQ:NAUT | 28.65M | -37.2% | -5.1% | N/A |
Immuneering Corporation Fair Value Envelope
Related Guides
Continue your IMRX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.